ClinicalTrials.gg

Program

lacutoclax

Also written as “LP-108”, “Lacutoclax” and “Lacutoclax+Rocbrutinib”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by Lupeng Pharmaceutical.

Furthest: phase 2, since May 20, 20264 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lupeng Pharmaceutical43 open or runningphase 2since May 20, 2026Oct 18, 2019Dec 31, 2027phase 1 · NCT05641259

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2019First study: phase 1 study in RecurrenceFirst studyNCT04139434 · 32 enrolled · United States, Spain
  2. Nov 17, 2022Phase 1 study in Leukemia, Myeloid, AcuteNCT05641259 · 198 planned · China
  3. May 20, 20262 phase 2 studiesPhase 2 reachedNCT07609862, NCT07609823

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT05641259
  2. Mar 30, 2028Primary completion: phase 2 study in RecurrenceNCT07609823
  3. Jun 30, 2029Primary completion: phase 2 study in Lymphoma, Mantle-CellNCT07609862

TargetBeta

BCL2 →read by rule
“The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).”study text, by rule · the study

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
venetoclaxruleAbbViephase 483
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
surzetoclaxAbbViephase 23
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07609862Lymphoma, Mantle-Cell · China2RecruitingJun 30, 202992
NCT07609823Recurrence · China2RecruitingMar 30, 202875
NCT05641259Leukemia, Myeloid, Acute · China1RecruitingDec 31, 2027198
NCT04139434Recurrence · United States, Spain1CompletedDec 19, 202532

How it is read

Names in the registry

  • “LP-108”, 2 entries
  • “Lacutoclax”, 1 entry
  • “Lacutoclax+Rocbrutinib”, 1 entry
  • “LP-108 and azacitidine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.